Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. EXC
5. SKA-B
6. PBA
7. CCH:LN
8. META
9. BAJAJHFL:I
10. CCHGY

Go back to Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh

Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines

December 5, 2019 8:02 AM EST

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown)... More

After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)

December 3, 2019 6:02 PM EST

After-Hours Movers

HealthEquity (NASDAQ: HQY) 12.7% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.

Revance Therapeutics, Inc. (Nasdaq: RVNC) 10.7% LOWER; announced a proposed underwritten public offering of its common stock. The Company intends to use the net... More

Goldman Sachs Starts Revance Therapeutic (RVNC) at Buy

December 2, 2019 4:30 AM EST

Goldman Sachs analyst Terence Flynn initiates coverage on Revance Therapeutic (NASDAQ: RVNC) with a Buy rating and a price target of $25.00.


For an analyst ratings summary and ratings history on Revance Therapeutic click here. For more ratings news on Revance Therapeutic click here.


Shares of Revance Therapeutic closed at $17.90 yesterday.

... More